Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmaceutical Therapy

Background:

• The advent of somatostatin receptor (SSTR) radiopharmaceuticals for PET imaging and peptide receptor radionuclide therapy (PRRT) marks a new era in neuroendocrine neoplasm (NEN) management.
• The transition from SSTR-based gamma-scintigraphy to PET imaging necessitates re-evaluation of traditional scoring systems like the Krenning score for PRRT eligibility due to PET's enhanced sensitivity.

Purpose of the Study:

• To comprehensively review the current role of SSTR PET in the diagnosis and management of NENs.
• To discuss the implications of SSTR PET's higher sensitivity compared to planar scintigraphy for PRRT eligibility.
• To evaluate the utility of SSTR PET in response assessment and outcome prediction in NEN patients.

Main Methods:

• Literature review of studies on SSTR PET imaging and PRRT for NENs.
• Analysis of the relationship between SSTR PET findings and conventional imaging modalities.
• Examination of current guidelines and emerging evidence for SSTR PET in patient selection, response assessment, and outcome prediction.

Main Results:

• SSTR PET offers superior sensitivity over planar scintigraphy, impacting PRRT eligibility criteria.
• The role of SSTR PET in assessing treatment response and predicting outcomes is still under active investigation.
• A standardized reporting template for SSTR PET is proposed to improve consistency.

Conclusions:

• SSTR PET is integral to modern NEN management, from diagnosis to therapy selection.
• Further research is needed to fully establish SSTR PET's role in response assessment and prognostication.
• Standardized reporting of SSTR PET is crucial for consistent clinical application.